SYNTRIX BIOSYSTEMS, INC.

Company Information
Address 215 CLAY ST NW, STE B-5
AUBURN, WA, 98001-4213


Information

DUNS: 114845659

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

    Amount: $300,000.00

    The chemokine receptors CXCR and CXCR CXCR are validated as having essential roles in the growth survival motility invasion and angiogenesis of human melanoma which secretes abundant amount ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Efficacy and resistance mechanisms of LD-aminopterin in psoriasis

    Amount: $1,139,730.00

    DESCRIPTION provided by applicant Psoriasis is a chronic genetically influenced remitting and relapsing scaly and inflammatory skin disorder that affects of the worldandapos s population re ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  3. Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine

    Amount: $1,988,014.00

    DESCRIPTION provided by applicant From the utilization of the Schedule II opioids codeine OxyContin and fentanyl declined significantly down about for all three drugs In sharp co ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  4. Phase II clinical evaluation of Omnitram in neuropathic pain

    Amount: $1,499,999.00

    DESCRIPTION provided by applicant Neuropathic pain is caused by damage to the peripheral nerves as occurs in diabetic neuropathy Neuropathic pain is difficult to treat and many patients have pai ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  5. Phase II clinical evaluation of Omnitram in neuropathic pain

    Amount: $224,997.00

    DESCRIPTION provided by applicant Neuropathic pain is caused by damage to the peripheral nerves as occurs in diabetic neuropathy Neuropathic pain is difficult to treat and many patients have pai ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  6. Efficacy and resistance mechanisms of LD-aminopterin in psoriasis

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resu ...

    SBIRPhase I2014Department of Health and Human Services
  7. Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

    Amount: $1,793,961.00

    DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with over 25 million prescriptions and 565 million in retail sales in 2009, making it among the best selling generic d ...

    SBIRPhase II2012Department of Health and Human Services
  8. Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD

    Amount: $3,846,324.00

    DESCRIPTION (provided by applicant): SX-576 is a small molecule CXCR1/2 antagonist that potently blocks the migration of neutrophils to sites of injury and/or inflammation. SX-576 is being developed a ...

    SBIRPhase II2011Department of Health and Human Services
  9. Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB

    Amount: $557,508.00

    DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb) is a notorious pathogen whose increasing resistance to antibiotics and heightened lethality in combination with AIDS makes it a ma ...

    SBIRPhase I2011Department of Health and Human Services
  10. 99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis

    Amount: $590,144.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) occurs in 2,100,000 people in the United States, and is associated with progressive joint destruction, functional disability and decrease ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government